Skip to main content
Equibles

Tina S. Nova, Ph.D.

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Tina S. Nova, Ph.D.

Veracyte, Inc. reported in an 8-K filed August 8, 2023 that Tina S. Nova, Ph.D. resigned as General Manager, Urological Cancers, effective September 3, 2023.

“On August 4, 2023, the Company and Tina S. Nova, Ph.D. agreed that Dr. Nova will resign from her position as General Manager, Urological Cancers of the Company effective as of September 3, 2023, and transition into an advisor role with the Company effective as of September 4, 2023 (the "Transition Date.").”
Veracyte, Inc. Form 8-K, filed August 8, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.